German gov’t deals blow to Sanofi-Aventis’ Acomplia

Share this article:
Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug. The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker. “Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement. Sanofi has argued that, since it helps lower a person's risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.